Oncology Pharma

Incyte Corporation

Incyte Corporation is an oncology-focused biopharmaceutical company based in Wilmington, Delaware, best known for developing ruxolitinib, the first FDA-approved JAK1/JAK2 inhibitor, which became a standard of care for myelofibrosis and polycythemia vera. The company's research programme spans inhibitors of JAK, PI3K-delta, IDO1, and FGFR pathways, addressing haematologic malignancies and solid tumours. Incyte actively collaborates with academic cancer centres, including the National Cancer Institute cooperative groups, and co-publishes translational data from biomarker-driven clinical trials. Researchers at partner institutions gain early access to investigational compounds for combination studies, and the company's clinical-grade analytics resources support academic biomarker research.

Industry

Oncology Pharma →